|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity.
|
29273807 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Targeting the tumor-restricted, glycosylation-dependent Siglec-9 axis may unleash this intratumoral T-cell subset, while confining T-cell activation to the tumor microenvironment.
|
30988027 |
2019 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Here we found that this cancer-specific MUC1 glycoform, through engagement of Siglec-9, 'educated' myeloid cells to release factors associated with determination of the tumor microenvironment and disease progression.
|
27595232 |
2016 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Here we used affinity chromatography of tumor cell extracts to identify LGALS3BP as a novel sialic acid-dependent ligand for human Siglec-9 and for other immunomodulatory Siglecs, such as Siglec-5 and Siglec-10.
|
25320078 |
2014 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Tumor-associated MUC1 binds to Siglec-9, which is expected to mediate tumor cell growth and negative immunomodulation.
|
24924635 |
2014 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Supporting this hypothesis, Siglec-9-expressing myelomonocytic cells found in human tumor samples were accompanied by a strong up-regulation of Siglec-9 ligands.
|
25225409 |
2014 |
|
Chronic Obstructive Airway Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Influence of SIGLEC9 polymorphisms on COPD phenotypes including exacerbation frequency.
|
27878892 |
2017 |
|
Chronic Obstructive Airway Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
In conclusion, Siglec-9 was complementarily increased to induce a negative feedback loop to limit neutrophil activation in COPD, sSiglce-9 enhanced neutrophil ROS and chemotaxis toward IL-8 likely via competitively inhibiting ligands binding to Siglec-9.
|
28860481 |
2017 |
|
Arteriosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Changes in Siglec-9 sialoglycan ligand expression on vascular endothelial cells may be a natural response to the initial steps of atherosclerosis and might be a potential target to regulate inflammation in diabetic angiopathy.
|
30471282 |
2019 |
|
Atherosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Changes in Siglec-9 sialoglycan ligand expression on vascular endothelial cells may be a natural response to the initial steps of atherosclerosis and might be a potential target to regulate inflammation in diabetic angiopathy.
|
30471282 |
2019 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Targeting Siglec-7 and Siglec-9, or the sialic acid coated tumor cell surface is therefore being investigated as a novel therapeutic approach to enhance the NK cell response against cancer.
|
31143186 |
2019 |
|
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Glioblastoma EVs showed significant binding to Siglec-9, which is highly expressed on DCs.
|
31489145 |
2019 |
|
melanoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, here, we report that the majority of intratumoral, but not peripheral blood, cytotoxic CD8<sup>+</sup> T cells expressed Siglec-9 in melanoma.
|
30988027 |
2019 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Glioblastoma EVs showed significant binding to Siglec-9, which is highly expressed on DCs.
|
31489145 |
2019 |
|
Childhood Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Glioblastoma EVs showed significant binding to Siglec-9, which is highly expressed on DCs.
|
31489145 |
2019 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Targeting Siglec-7 and Siglec-9, or the sialic acid coated tumor cell surface is therefore being investigated as a novel therapeutic approach to enhance the NK cell response against cancer.
|
31143186 |
2019 |
|
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
Glioblastoma EVs showed significant binding to Siglec-9, which is highly expressed on DCs.
|
31489145 |
2019 |
|
Asthma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeting Neutrophils in Severe Asthma via Siglec-9.
|
29306942 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
T cell expression of Siglec-9 in NSCLC patients correlated with reduced survival, and Siglec-9 polymorphisms showed association with the risk of developing lung and colorectal cancer.
|
30130255 |
2018 |
|
Chikungunya Fever
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression of Siglec-9 on monocytes; which can modulate oxidative stress is studied along with intracellular reactive oxygen species (ROS), cellular lipid and protein damage markers in chikungunya patients with/without persisting polyarthralgia along with healthy controls.
|
29898618 |
2018 |
|
Colorectal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
T cell expression of Siglec-9 in NSCLC patients correlated with reduced survival, and Siglec-9 polymorphisms showed association with the risk of developing lung and colorectal cancer.
|
30130255 |
2018 |
|
Guillain-Barre Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Transgenic mice expressing the soluble form of Siglec-9 showed significant resistance against GBS infection and remarkable suppression of MUC1 expressing tumor proliferation.
|
29342882 |
2018 |
|
Lung diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Given that neutrophils are probably a major culprit in the generation and perpetuation of inflammation, targeting Siglec-9 could be beneficial for the treatment of severe asthma, chronic obstructive pulmonary disease, and related pulmonary disorders characteristic of neutrophilia.
|
29306942 |
2018 |
|
Complete atrioventricular block
|
0.010 |
Biomarker
|
disease |
BEFREE |
Neutralization of Siglec-9 restored cytokine synthesis and degranulation of NK cells from CHB patients.
|
29899741 |
2018 |